To transfer the generic pharmaceuticals business to a collaborative organization, a two-step absorption-type split will be carried out, after which the target business will be transferred to the collaborative organization. The effective date is March 31, 2027, and the share transfer is scheduled to be executed on April 1, 2027. This is carried out in the context of implementing the mid-term plan under Vision 110 Stage2.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4569","jir_company_name":"KYORIN Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-09-30","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/09\/4569-20260930-01.pdf","jir_short_summary":"To transfer the generic pharmaceuticals business to a collaborative organization, a two-step absorption-type split will be carried out, after which the target business will be transferred to the collaborative organization. The effective date is March 31, 2027, and the share transfer is scheduled to be executed on April 1, 2027. This is carried out in the context of implementing the mid-term plan under Vision 110 Stage2.","jir_summary":"### Overview of the Transaction\nKYORIN Pharmaceutical intends to transfer its generic pharmaceuticals business to a collaborative organization by conducting Absorption-Type Split \u2460, in which the KYORIN Pharmaceutical Group Factory will be the splitting company and the target company will be the successor company, and Absorption-Type Split \u2461, in which the target company will be the splitting company and the KYORIN Pharmaceutical Group Factory will be the successor company. Subsequently, the issued shares of the target company will be transferred to the collaborative organization. The schedule is: contract conclusion in Q3 of fiscal 2026; effective date March 31, 2027; share transfer execution scheduled for April 1, 2027.\n\n### Outlook and Impact\nThis transaction will optimize the business portfolio and allow the company to concentrate resources on new pharmaceutical businesses, while a special loss associated with the business transfer is expected to be recorded in the second quarter. The specific amount is not yet determined; the company will promptly disclose any matters that should be disclosed. The transaction promotes implementation of the medium-to-long-term plan under Vision 110 -Stage2-.","jir_financial_highlights":"Consolidated Net Sales: Unknown (Unknown)\nNet Assets: Unknown (Unknown)\nExtraordinary Loss Associated with This Share Transfer: A loss on business transfer related to this transaction is expected to be recorded as an extraordinary loss in the consolidated accounting period for the second quarter (interim period) (Expected)","jir_category":"","jir_hashtags":"#KYORINPharmaceuticalCoLtdData, #BusinessSuccession, #AbsorptionTypeSplit, #BusinessRestructuring","jir_key_figures":"Absorption-type split schedule: March 31, 2027 (scheduled)\nShare transfer execution date: April 1, 2027 (scheduled)\nNumber of shares held after this share transfer: 0 shares (voting rights ownership ratio: 0%)","jir_meta_title":"KYORIN Pharmaceutical Co., Ltd. \u2014 Business Portfolio Optimization via Transfer of Generic Pharmaceuticals Business\uff5cSeptember 2026","jir_meta_description":"KYORIN Pharmaceutical announces an absorption-type split and share transfer to transfer its generic pharmaceuticals business to a collaborative organization. Effective date is March 31, 2027, with transfer execution on April 1, 2027. Explains the implementation under Vision 110 Stage2 and expected impact.","jir_og_title":"KYORIN Pharmaceutical Announces Transfer of Generic Pharmaceuticals Business\uff5cSeptember 2026","jir_og_description":"Announces an absorption-type split and share transfer to transfer the generic pharmaceuticals business to a collaborative organization. Effective date March 31, 2027; transfer on April 1, 2027. Measures to execute Vision 110 Stage2.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":16660,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"corporate_restructuring","footnotes":""},"sector":[],"importance":[],"class_list":["post-125029","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n